Our product developments are driven forward within the framework of interdisciplinary projects. At the beginning there is always a vision to make something better, healthier or more sustainable with the help of our products.
Our development pipeline is filled with numerous ideas that we evaluate until the best product is ready to hit the market.
Development of DENARASE
2009 - 2012
Start of DENARASE project: Strain selection, development of upstream and purification process
Project started: Application of endonucleases for DNA removal during protein purification
c-LEcta‘s Bacillus strain, an endotoxin-free expression host, yielded highly active DENARASE product. Purity of ≥99 % was achieved after purification.
Manufacturing of DENARASE under GMP conditions
Requirements of the biopharmaceutical industry for a GMP product were identified
Partnering with a contract manufacturing organization (CMO) to produce DENARASE under EU GMP conditions
Manufacturing process free of animal derived raw materials and antibiotics was established
Product launch of DENARASE
DENARASE fulfills highest quality standards for biopharmaceutical manufacturing
Starting to build a global sales and distribution network for life science customers
Growth of internal quality, production, distribution and sales functions
First DENARASE-related patents granted
Patents were successfully granted for the production technology of DENARASE based on recombinant expression in Bacillus
Launch of DENARASE ELISA Kit
Launch of own ELISA kit for the detection of S. marcescens endonucleases in process-derived samples
Fastest and most sensitive ELISA kit available on the market
Focused support for customers developing and manufacturing COVID-19 vaccines at unprecedented speed
Concerted efforts of c-LEcta teams with COVID-19 vaccine customers succeeded in the delivery of large, unplanned quantities of DENARASE on short timelines
c-LEcta’s resilient manufacturing and distribution network kept COVID-19 related supply issues to general customers at an absolute minimum
Drug Master File for DENARASE accepted by FDA
Dedicated regulatory support for US-market approvals of pharmaceutical products via own US FDA Drug Master File.
In addition, certified compliance with the EXCiPACT and ANSI NSF 363 Standard (meeting GMP for pharmaceutical excipients)
Global application of DENARASE and ELISA kit in biopharmaceutical manufacturing
DENARASE and ELISA kit are established highest-quality products, applied in the manufacturing of viral vectors for Gene therapies and vaccines:
> 150 customers in > 30 countries
DENARASE is applied in 4 Commercial and 40+ Clinical Phase I-III viral vector manufacturing processes